The
latest MTRAC committee meeting discussed the prescribing of perampanel adjunctive therapy and zonisamide monotherapy
for the treatment of partial (or focal) seizures in epilepsy.
It was the committee’s opinion that perampanel should only be
used in a tertiary care setting, and that patients receiving treatment with
perampanel were likely to receive continued specialist supervision and
treatment.
With zonisamide the committee agreed that zonisamide monotherapy
should only be considered when other NICE-recommended first- and second-line
treatment options have proved ineffective or are not tolerated.
Each of the commissioning support sheets can be accessed from http://centreformedicinesoptimisation.co.uk/mtrac/committee-recommendations
The next committee meeting is on the 24th October and
will be discussing nalmefene for the treatment of alcohol dependency and
melatonin for the treatment of primary insomnia.
